Sugi Predict

Sugi Predict / Compounds / SCHEMBL3618656

SCHEMBL3618656

SCHEMBL3618656

Cc1noc(C)c1S(=O)(=O)Nc1ccc(N2CCNCC2)cc1NS(=O)(=O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 8/20 0.51
▸ POLB P06746 3/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ NMT1 P30419 1/20 0.47
▸ GFER P55789 1/20 0.47
▸ HTT P42858 2/20 0.46
▸ ACLY P53396 1/20 0.46
▸ LMNA P02545 2/20 0.45
▸ PKM P14618 1/20 0.45
▸ KAT6A Q92794 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ BRD4 O60885 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3624526 0.99 HTR6 (0.50) HTR6POLBALDH1A1NMT1GFER
SCHEMBL3622503 0.96 POLB (0.48) HTR6POLBALDH1A1NMT1GFER
Hydrochloric Acid SCHEMBL3613245 0.95 POLB (0.47) HTR6POLBALDH1A1NMT1GFER
Hydrochloric Acid SCHEMBL6862743 0.87 HTR6 (0.47) HTR6POLBALDH1A1NMT1GFER
SCHEMBL3612770 0.86 POLB (0.46) HTR6POLBALDH1A1NMT1GFER
Hydrochloric Acid SCHEMBL3615068 0.85 POLB (0.45) HTR6POLBALDH1A1NMT1GFER
SCHEMBL3618583 0.83 HTR6 (0.56) HTR6LMNAKAT6AMAPT
SCHEMBL3619622 0.82 HTR6 (0.60) HTR6ALDH1A1KAT6AMAPT
Hydrochloric Acid SCHEMBL3618643 0.82 HTR6 (0.55) HTR6LMNAKAT6AMAPT
Hydrochloric Acid SCHEMBL3622558 0.81 HTR6 (0.59) HTR6KAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319097-B2 Treatment of type II diabetes with benzenesulfonamide substituted with an N-heterocycle: N-[2-amino-5-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide, N-[4-amino-5-(piperazinyl)phenyl]benzenesulfonamide, 3-amino-4-(5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-N-phenyl-benzenesulfonamide hydrochloride BIOVITRUM AB (SE) 2008-01-15 — — US claimed
US-7173035-B2 Arylsulfonamide compounds BIOVITRUM AB (SE) 2007-02-06 — — US claimed
US-20050288275-A1 New compounds BIOVITRUM AB, A SWEDEN CORPORATION 2005-12-29 — — US claimed
EP-1406884-A1 ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS BIOVITRUM AB (SE) 2004-04-14 — — EP claimed
US-20030149020-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2003-08-07 — — US claimed
US-20030149019-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2003-08-07 — — US claimed
WO-2002092585-A1 NOVEL, ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS BIOVITRUM AB (SE) 2002-11-21 — — WO claimed
US-7718650-B2 Aryl sulfonamide compounds for treating obesity BIOVITRUM AB (SE) 2010-05-18 — — US disclosed
US-7566715-B2 Substituted sulfonamide compounds useful for the prophylaxis and treatment of conditions relating to obesity, type II diabetes and/or disorders of the central nervous system BIOVITRUM AB (SE) 2009-07-28 — — US disclosed
US-20080096873-A1 NEW COMPOUNDS BIOVITRUM AB, A SWEDEN CORPORATION 2008-04-24 — — US disclosed
US-7319097-B2 Treatment of type II diabetes with benzenesulfonamide substituted with an N-heterocycle: N-[2-amino-5-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide, N-[4-amino-5-(piperazinyl)phenyl]benzenesulfonamide, 3-amino-4-(5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-N-phenyl-benzenesulfonamide hydrochloride BIOVITRUM AB (SE) 2008-01-15 — — US disclosed
US-7173035-B2 Arylsulfonamide compounds BIOVITRUM AB (SE) 2007-02-06 — — US disclosed
US-20060009446-A1 New compounds BIOVITRUM AB, A SWEDEN CORPORATION 2006-01-12 — — US disclosed
US-20050288275-A1 New compounds BIOVITRUM AB, A SWEDEN CORPORATION 2005-12-29 — — US disclosed
US-6969710-B2 Compounds BIOVITRUM AB (SE) 2005-11-29 — — US disclosed
CN-1531531-A Novel arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders �Ȱ�ά����ķ�ɷݹ�˾ 2004-09-22 — — CN disclosed
EP-1406884-A1 ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS BIOVITRUM AB (SE) 2004-04-14 — — EP disclosed
US-20030149020-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2003-08-07 — — US disclosed
US-20030149019-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2003-08-07 — — US disclosed
WO-2002092585-A1 NOVEL, ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS BIOVITRUM AB (SE) 2002-11-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149020-A1 New compounds GPR119, SULT2A1, NAT1 HTR6 436/4885POLB 3867/4885ALDH1A1 438/4885
US-20030149019-A1 New compounds GPR119, SULT2A1, NAT1 HTR6 436/4885POLB 3867/4885ALDH1A1 438/4885
US-20060009446-A1 New compounds GPR119, SULT2A1, STS HTR6 484/4885POLB 3841/4885ALDH1A1 818/4885
US-20080096873-A1 NEW COMPOUNDS GPR119, SULT2A1, STS HTR6 484/4885POLB 3841/4885ALDH1A1 818/4885
US-20050288275-A1 New compounds GPR119, SULT2A1, STS HTR6 484/4885POLB 3841/4885ALDH1A1 818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.